AIDS Clinical Trial
— HIV-CORE 004Official title:
A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.
Verified date | May 2016 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | Kenya: Pharmacy and Poisons Board |
Study type | Interventional |
The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation.
Status | Completed |
Enrollment | 72 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Healthy adults aged 18-50 - Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. - Written informed consent. - Willing to undergo HIV-1 testing, counselling and receive test results. - All female volunteers must be willing to undergo urine pregnancy tests - If sexually active using an effective method of contraception until at least 4 months after the last vaccination. - Willing to forgo donating blood during the study. Exclusion Criteria: - Any relevant abnormality on history or examination including history of immunodeficiency or autoimmune disease, or use of systemic corticosteroids, immunosuppressive, antiviral, anticancer or other medication that, in the opinion of the Principal Investigator or designee, is clinically significant, within the previous 6 months. (Note: use of inhaled steroids for asthma or use of topical steroids for localized skin conditions will not exclude a volunteer from participation.) - Any clinically significant acute or chronic medical condition that is considered progressive or, in the opinion of the Principal Investigator or designee, would make the volunteer unsuitable for the study. - Any of the following abnormal laboratory parameters (1 abnormal test may be repeated once if thought to be due to a temporary condition): - Haematology - Haemoglobin < 9.0 g/dl for women and <11.0 g/dl for men - Absolute Neutrophil Count (ANC) = 1000 /mm3 (= 1 x 109 /l) - Absolute Lymphocyte Count (ALC) = 600 /mm3 (=0.6 x 109 /l) - Platelets =100,000 /mm3, = 550,000 /mm3 (= 100 /l, = 550 /l) - Biochemistry - Creatinine > 1.3 x upper limit of normal (ULN) - Aspartate aminotransferase (AST) > 2.5 x ULN - Alanine aminotransferase (ALT) > 2.5 x ULN - Urinalysis- Clinically significant abnormal dipstick confirmed by microscopy: - Protein = 2+ or more - Blood = 2+ or more (for women: before or after menses) - Confirmed HIV-1 or HIV-2 infection. - If female, pregnant or planning a pregnancy any time from enrolment to 4 months after the last vaccination; or lactating. - Receipt of live attenuated vaccine within the previous 60 days or planned receipt at any time until 60 days after vaccination with Investigational Medicinal Product (IMP) or receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt at any time until 14 days after vaccination with the IMP. - Receipt of blood transfusion or blood products within the previous 6 months. - Participation in another clinical trial of an IMP currently or within the previous 3 months or expected participation during this study. - Receipt of any investigational HIV-1 vaccine within the last 6 years. - History of severe or very severe local or systemic reactogenicity events after vaccination, or history of severe or very severe allergic reactions. - Confirmed diagnosis of acute or chronic hepatitis B virus infection (spontaneous clearance leading to natural immunity, indicated by antibodies to core + antigens, is not an exclusion criterion); confirmed diagnosis of hepatitis C virus infection; untreated syphilis. - Smallpox vaccination within the previous 3 years. - Major psychiatric illness in the previous 3 years. - History of allergy or hypersensitivity to latex, chronic skin problems such as eczema or psoriasis, or skin and subcutaneous tissue thickness > 40 mm as assessed by skin pinch test in either deltoid region. - Presence of an implantable device - Current use of any electronic stimulation device. Therapeutic or traumatic metal implant in either deltoid region. - History of, or known active cardiac disease or a heart condition under the care of a doctor. Note: Slight physiological variation of normal resting heart rate (60 - 100 beats/minute) with respiration is NOT excluded. - History of syncope or fainting episode within 1 year of study entry. - Seizure disorder or any history of prior seizure. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Kenya | KAVI-Kangemi clinic | Nairobi |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | European and Developing Countries Clinical Trials Partnership (EDCTP), Ichor Medical Systems Incorporated, International AIDS Vaccine Initiative, Karolinska Institutet, University of Nairobi |
Kenya,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vaccine Safety | Proportion of volunteers who develop a grade 3 or 4 local reaction. Proportion of volunteers who develop a grade 3 or 4 systemic reaction | 44 weeks | Yes |
Secondary | Vaccine immunogenicity | T cell responses will be determined initially by interferon-gamma enzyme-linked immunospot assay | 44 weeks | No |
Secondary | Vaccine Safety | A descriptive summary of grade 3 of 4 local and systemic events including laboratory abnormalities. A descriptive summary of serious adverse events, including laboratory abnormalities |
44 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02606344 -
Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV
|
N/A | |
Completed |
NCT01053598 -
Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting
|
N/A | |
Completed |
NCT01348308 -
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00951795 -
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
|
N/A | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Withdrawn |
NCT00347750 -
Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations
|
Phase 3 | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Withdrawn |
NCT00340223 -
HLA-B35 Alleles and AIDS
|
N/A | |
Completed |
NCT01084395 -
Reducing HIV Risk Among Mexican Youth
|
N/A | |
Completed |
NCT00144352 -
In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults
|
Phase 4 | |
Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
Completed |
NCT00341172 -
The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
|
||
Recruiting |
NCT06145841 -
Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
|
||
Completed |
NCT03633721 -
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women
|
Phase 2 | |
Completed |
NCT04567693 -
Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
|
N/A | |
Completed |
NCT03023033 -
Supporting Attendance for Facility Delivery and Infant Health
|
N/A |